{"DataElement":{"publicId":"5990037","version":"1","preferredName":"Exocrine Pancreatic Cancer AJCC Edition 8 Clinical Tumor T Category","preferredDefinition":"Extent of the primary exocrine pancreatic carcinoma based on information obtained from the date of cancer diagnosis until the start of definitive treatment, or within four months (whichever is shorter), using AJCC Ed. 8 criteria.","longName":"EPAN_AJC8_CLN_T_CAT","context":"NCI Standards","contextVersion":"1","DataElementConcept":{"publicId":"3452359","version":"1","preferredName":"Pancreas Neoplasm Clinical T Stage","preferredDefinition":"A non-encapsulated elongated and lobulated organ, extending from the concavity of the duodenum to the spleen; it consists of a head, an elongated body, and a tail. It contains two functional components: an exocrine component that secretes juices into the intestine and an endocrine component that secretes hormones (insulin and glucagon)._A benign or malignant tissue growth resulting from uncontrolled cell proliferation. Benign neoplastic cells resemble normal cells without exhibiting significant cytologic atypia, while malignant cells exhibit overt signs such as dysplastic features, atypical mitotic figures, necrosis, nuclear pleomorphism, and anaplasia. Representative examples of benign neoplasms include papillomas, cystadenomas, and lipomas; malignant neoplasms include carcinomas, sarcomas, lymphomas, and leukemias._Relating to the examination and treatment of patients dependent on direct observation. The term may also refer to the institution (clinic) providing this activity._One criteria of the TMN staging system.  T refers to the extent of tumor involvement at the primary site (T, followed by a number indicating size and depth of invasion).","longName":"3452357v1.0:2207100v1.0","context":"NCI Standards","contextVersion":"1","ObjectClass":{"publicId":"3452357","version":"1","preferredName":"Pancreas Neoplasm","preferredDefinition":"A non-encapsulated elongated and lobulated organ, extending from the concavity of the duodenum to the spleen; it consists of a head, an elongated body, and a tail. It contains two functional components: an exocrine component that secretes juices into the intestine and an endocrine component that secretes hormones (insulin and glucagon).:A benign or malignant tissue growth resulting from uncontrolled cell proliferation. Benign neoplastic cells resemble normal cells without exhibiting significant cytologic atypia, while malignant cells exhibit overt signs such as dysplastic features, atypical mitotic figures, necrosis, nuclear pleomorphism, and anaplasia. Representative examples of benign neoplasms include papillomas, cystadenomas, and lipomas; malignant neoplasms include carcinomas, sarcomas, lymphomas, and leukemias.","longName":"C12393:C3262","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Pancreas","conceptCode":"C12393","definition":"An organ behind the lower part of the stomach that is the shape of a fish and about the size of a hand. It is a compound gland composed of both exocrine and endocrine tissues. The endocrine pancreas makes insulin so that the body can use glucose (sugar) for energy. The exocrine pancreas makes enzymes that help the body digest food. Spread all over the pancreas are areas called the Islets of Langerhans. The cells in these areas each have a special purpose. The alpha cells make glucagon, which raises the level of glucose in the blood; the beta cells make insulin; the delta cells make somatostatin. There are also PP cells and D1 cells, about which little is known.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Neoplasm","conceptCode":"C3262","definition":"A benign or malignant tissue growth resulting from uncontrolled cell proliferation. Benign neoplastic cells resemble normal cells without exhibiting significant cytologic atypia, while malignant cells exhibit overt signs such as dysplastic features, atypical mitotic figures, necrosis, nuclear pleomorphism, and anaplasia. Representative examples of benign neoplasms include papillomas, cystadenomas, and lipomas; malignant neoplasms include carcinomas, sarcomas, lymphomas, and leukemias.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"BF79E0A4-6392-D3E2-E040-BB89AD4323E5","latestVersionIndicator":"Yes","beginDate":"2012-05-07","endDate":null,"createdBy":"COOPERM","dateCreated":"2012-05-07","modifiedBy":"ONEDATA","dateModified":"2012-05-07","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"2207100","version":"1","preferredName":"Clinical T Stage","preferredDefinition":"Having to do with the examination and treatment of patients.:One criteria of the TMN staging system.  T refers to the extent of tumor involvement at the primary site (T, followed by a number indicating size and depth of invasion).","longName":"C25398:C25728","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Clinical","conceptCode":"C25398","definition":"Relating to the examination and treatment of patients dependent on direct observation.  The term may also refer to the institution (clinic) providing this activity.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"T Category","conceptCode":"C25728","definition":"One criteria of the TNM staging system. T refers to the extent of tumor involvement at the primary site (T, followed by a number indicating size and depth of invasion).","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F37D0429-183F-6787-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-03-29","endDate":null,"createdBy":"SBR","dateCreated":"2005-03-29","modifiedBy":"ONEDATA","dateModified":"2005-03-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008537","version":"1","preferredName":"Diagnosis","preferredDefinition":"the process of identifying a disease by the signs and symptoms (NCI Glossary).","longName":"DX","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B205508C-8324-69B0-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-17","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-17","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"BF79E0A4-63A0-D3E2-E040-BB89AD4323E5","latestVersionIndicator":"Yes","beginDate":"2012-05-07","endDate":null,"createdBy":"COOPERM","dateCreated":"2012-05-07","modifiedBy":"TAYLORT","dateModified":"2017-09-13","changeDescription":"9/13/17 tt transferred context; changed Reg Status to Qualified. Created for CRF standard harmonization. Released per final community approval. mc 5/15/12","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"6032755","version":"1","preferredName":"Exocrine Pancreatic Carcinoma American Joint Committee on Cancer Edition 8 T Category","preferredDefinition":"A finding about one or more characteristics of exocrine pancreatic cancer, following the rules of the TNM AJCC v8 classification system. This classification applies to pancreatic ductal adenocarcinoma, acinar cell carcinoma, intraductal papillary mucinous neoplasm with associated invasive carcinoma, intraductal tubulopapillary neoplasm with associated invasive carcinoma, colloid carcinoma, mucinous cystic neoplasm with associated invasive carcinoma, solid pseudopapillary neoplasm, large cell neuroendocrine carcinoma, small cell neuroendocrine carcinoma, and pancreatoblastoma. Well-differentiated neuroendocrine tumors are not staged using this staging system. (from AJCC 8th Ed.)_A group formed for the purpose of developing a system of clinical staging for cancer that is acceptable to the American medical profession and is compatible with other accepted classifications._One criteria of the TNM staging system.  T refers to the extent of tumor involvement at the primary site (T, followed by a number indicating size and depth of invasion)._A grouping of items based on some commonality or by user defined characteristics.","longName":"6032755v1.0","context":"NCI Standards","contextVersion":"1","type":"Enumerated","dataType":"CHARACTER","minLength":"2","maxLength":"3","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"T1c","valueDescription":"Exocrine Pancreatic Cancer pT1c TNM Finding v8","ValueMeaning":{"publicId":"6031330","version":"1","preferredName":"Exocrine Pancreatic Cancer pT1c TNM Finding v8","longName":"6031330","preferredDefinition":"Exocrine pancreatic cancer with tumor measuring 1-2 cm in greatest dimension. (from AJCC 8th Ed.)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Exocrine Pancreatic Cancer pT1c TNM Finding v8","conceptCode":"C134892","definition":"Exocrine pancreatic cancer with tumor measuring 1-2 cm in greatest dimension. (from AJCC 8th Ed.)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"5E845070-77A9-33E3-E053-F662850A3936","latestVersionIndicator":"Yes","beginDate":"2017-11-21","endDate":null,"createdBy":"TAYLORT","dateCreated":"2017-11-21","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"5F0A553E-3CB7-1093-E053-F662850AEC93","beginDate":"2017-11-28","endDate":null,"createdBy":"TAYLORT","dateCreated":"2017-11-28","modifiedBy":"ONEDATA","dateModified":"2017-11-28","deletedIndicator":"No"},{"value":"T1b","valueDescription":"Exocrine Pancreatic Cancer pT1b TNM Finding v8","ValueMeaning":{"publicId":"6031332","version":"1","preferredName":"Exocrine Pancreatic Cancer pT1b TNM Finding v8","longName":"6031332","preferredDefinition":"Exocrine pancreatic cancer with tumor measuring more than 0.5 cm and less than 1 cm in greatest dimension. (from AJCC 8th Ed.)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Exocrine Pancreatic Cancer pT1b TNM Finding v8","conceptCode":"C134891","definition":"Exocrine pancreatic cancer with tumor measuring more than 0.5 cm and less than 1 cm in greatest dimension. (from AJCC 8th Ed.)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"5E845070-77CF-33E3-E053-F662850A3936","latestVersionIndicator":"Yes","beginDate":"2017-11-21","endDate":null,"createdBy":"TAYLORT","dateCreated":"2017-11-21","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"5F0A553E-3CC1-1093-E053-F662850AEC93","beginDate":"2017-11-28","endDate":null,"createdBy":"TAYLORT","dateCreated":"2017-11-28","modifiedBy":"ONEDATA","dateModified":"2017-11-28","deletedIndicator":"No"},{"value":"T1a","valueDescription":"Exocrine Pancreatic Cancer pT1a TNM Finding v8","ValueMeaning":{"publicId":"6031334","version":"1","preferredName":"Exocrine Pancreatic Cancer pT1a TNM Finding v8","longName":"6031334","preferredDefinition":"Exocrine pancreatic cancer with tumor measuring 0.5 cm or less in greatest dimension. (from AJCC 8th Ed.)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Exocrine Pancreatic Cancer pT1a TNM Finding v8","conceptCode":"C134890","definition":"Exocrine pancreatic cancer with tumor measuring 0.5 cm or less in greatest dimension. (from AJCC 8th Ed.)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"5E845070-77F5-33E3-E053-F662850A3936","latestVersionIndicator":"Yes","beginDate":"2017-11-21","endDate":null,"createdBy":"TAYLORT","dateCreated":"2017-11-21","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"5F0A553E-3CCB-1093-E053-F662850AEC93","beginDate":"2017-11-28","endDate":null,"createdBy":"TAYLORT","dateCreated":"2017-11-28","modifiedBy":"ONEDATA","dateModified":"2017-11-28","deletedIndicator":"No"},{"value":"T4","valueDescription":"Exocrine Pancreatic Cancer pT4 TNM Finding v8","ValueMeaning":{"publicId":"6031324","version":"1","preferredName":"Exocrine Pancreatic Cancer pT4 TNM Finding v8","longName":"6031324","preferredDefinition":"Exocrine pancreatic cancer with tumor involving the celiac axis, superior mesenteric artery, and/or common hepatic artery, regardless of size. (from AJCC 8th Ed.)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Exocrine Pancreatic Cancer pT4 TNM Finding v8","conceptCode":"C134895","definition":"Exocrine pancreatic cancer with tumor involving the celiac axis, superior mesenteric artery, and/or common hepatic artery, regardless of size. (from AJCC 8th Ed.)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"5E845070-7737-33E3-E053-F662850A3936","latestVersionIndicator":"Yes","beginDate":"2017-11-21","endDate":null,"createdBy":"TAYLORT","dateCreated":"2017-11-21","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"5EFD0F19-4687-36EE-E053-F662850ACDFB","beginDate":"2017-11-27","endDate":null,"createdBy":"TAYLORT","dateCreated":"2017-11-27","modifiedBy":"ONEDATA","dateModified":"2017-11-27","deletedIndicator":"No"},{"value":"T3","valueDescription":"Exocrine Pancreatic Cancer pT3 TNM Finding v8","ValueMeaning":{"publicId":"6031326","version":"1","preferredName":"Exocrine Pancreatic Cancer pT3 TNM Finding v8","longName":"6031326","preferredDefinition":"Exocrine pancreatic cancer with tumor measuring more than 4 cm in greatest dimension. (from AJCC 8th Ed.)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Exocrine Pancreatic Cancer pT3 TNM Finding v8","conceptCode":"C134894","definition":"Exocrine pancreatic cancer with tumor measuring more than 4 cm in greatest dimension. (from AJCC 8th Ed.)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"5E845070-775D-33E3-E053-F662850A3936","latestVersionIndicator":"Yes","beginDate":"2017-11-21","endDate":null,"createdBy":"TAYLORT","dateCreated":"2017-11-21","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"5EFD0F19-4691-36EE-E053-F662850ACDFB","beginDate":"2017-11-27","endDate":null,"createdBy":"TAYLORT","dateCreated":"2017-11-27","modifiedBy":"ONEDATA","dateModified":"2017-11-27","deletedIndicator":"No"},{"value":"T2","valueDescription":"Exocrine Pancreatic Cancer pT2 TNM Finding v8","ValueMeaning":{"publicId":"6031328","version":"1","preferredName":"Exocrine Pancreatic Cancer pT2 TNM Finding v8","longName":"6031328","preferredDefinition":"Exocrine pancreatic cancer with tumor measuring more than 2 cm and 4 cm or less in greatest dimension. (from AJCC 8th Ed.)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Exocrine Pancreatic Cancer pT2 TNM Finding v8","conceptCode":"C134893","definition":"Exocrine pancreatic cancer with tumor measuring more than 2 cm and 4 cm or less in greatest dimension. (from AJCC 8th Ed.)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"5E845070-7783-33E3-E053-F662850A3936","latestVersionIndicator":"Yes","beginDate":"2017-11-21","endDate":null,"createdBy":"TAYLORT","dateCreated":"2017-11-21","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"5EFD0F19-469B-36EE-E053-F662850ACDFB","beginDate":"2017-11-27","endDate":null,"createdBy":"TAYLORT","dateCreated":"2017-11-27","modifiedBy":"ONEDATA","dateModified":"2017-11-27","deletedIndicator":"No"},{"value":"T1","valueDescription":"Exocrine Pancreatic Cancer pT1 TNM Finding v8","ValueMeaning":{"publicId":"6031337","version":"1","preferredName":"Exocrine Pancreatic Cancer pT1 TNM Finding v8","longName":"6031337","preferredDefinition":"Exocrine pancreatic cancer with tumor measuring 2 cm or less in greatest dimension. (from AJCC 8th Ed.)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Exocrine Pancreatic Cancer pT1 TNM Finding v8","conceptCode":"C134889","definition":"Exocrine pancreatic cancer with tumor measuring 2 cm or less in greatest dimension. (from AJCC 8th Ed.)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"5E845070-781B-33E3-E053-F662850A3936","latestVersionIndicator":"Yes","beginDate":"2017-11-21","endDate":null,"createdBy":"TAYLORT","dateCreated":"2017-11-21","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"5EFD0F19-46A5-36EE-E053-F662850ACDFB","beginDate":"2017-11-27","endDate":null,"createdBy":"TAYLORT","dateCreated":"2017-11-27","modifiedBy":"ONEDATA","dateModified":"2017-11-27","deletedIndicator":"No"},{"value":"Tis","valueDescription":"Exocrine Pancreatic Cancer pTis TNM Finding v8","ValueMeaning":{"publicId":"6031339","version":"1","preferredName":"Exocrine Pancreatic Cancer pTis TNM Finding v8","longName":"6031339","preferredDefinition":"Exocrine pancreatic cancer with a finding of carcinoma in situ. This includes high-grade pancreatic intraepithelial neoplasia (PanIn-3), intraductal papillary mucinous neoplasm with high-grade dysplasia, intraductal tubulopapillary neoplasm with high-grade dysplasia, and mucinous cystic neoplasm with high-grade dysplasia. (from AJCC 8th Ed.)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Exocrine Pancreatic Cancer pTis TNM Finding v8","conceptCode":"C134888","definition":"Exocrine pancreatic cancer with a finding of carcinoma in situ. This includes high-grade pancreatic intraepithelial neoplasia (PanIn-3), intraductal papillary mucinous neoplasm with high-grade dysplasia, intraductal tubulopapillary neoplasm with high-grade dysplasia, and mucinous cystic neoplasm with high-grade dysplasia. (from AJCC 8th Ed.)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"5E845070-7841-33E3-E053-F662850A3936","latestVersionIndicator":"Yes","beginDate":"2017-11-21","endDate":null,"createdBy":"TAYLORT","dateCreated":"2017-11-21","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"5EFD0F19-46AF-36EE-E053-F662850ACDFB","beginDate":"2017-11-27","endDate":null,"createdBy":"TAYLORT","dateCreated":"2017-11-27","modifiedBy":"ONEDATA","dateModified":"2017-11-27","deletedIndicator":"No"},{"value":"T0","valueDescription":"Exocrine Pancreatic Cancer pT0 TNM Finding v8","ValueMeaning":{"publicId":"6031341","version":"1","preferredName":"Exocrine Pancreatic Cancer pT0 TNM Finding v8","longName":"6031341","preferredDefinition":"Exocrine pancreatic cancer with no evidence of primary tumor. (from AJCC 8th Ed.)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Exocrine Pancreatic Cancer pT0 TNM Finding v8","conceptCode":"C134887","definition":"Exocrine pancreatic cancer with no evidence of primary tumor. (from AJCC 8th Ed.)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"5E845070-7867-33E3-E053-F662850A3936","latestVersionIndicator":"Yes","beginDate":"2017-11-21","endDate":null,"createdBy":"TAYLORT","dateCreated":"2017-11-21","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"5EFD0F19-46B9-36EE-E053-F662850ACDFB","beginDate":"2017-11-27","endDate":null,"createdBy":"TAYLORT","dateCreated":"2017-11-27","modifiedBy":"ONEDATA","dateModified":"2017-11-27","deletedIndicator":"No"},{"value":"TX","valueDescription":"Exocrine Pancreatic Cancer pTX TNM Finding v8","ValueMeaning":{"publicId":"6031343","version":"1","preferredName":"Exocrine Pancreatic Cancer pTX TNM Finding v8","longName":"6031343","preferredDefinition":"Exocrine pancreatic cancer in which the primary tumor cannot be assessed. (from AJCC 8th Ed.)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Exocrine Pancreatic Cancer pTX TNM Finding v8","conceptCode":"C134886","definition":"Exocrine pancreatic cancer in which the primary tumor cannot be assessed. (from AJCC 8th Ed.)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"5E845070-788D-33E3-E053-F662850A3936","latestVersionIndicator":"Yes","beginDate":"2017-11-21","endDate":null,"createdBy":"TAYLORT","dateCreated":"2017-11-21","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"5EFD0F19-46C3-36EE-E053-F662850ACDFB","beginDate":"2017-11-27","endDate":null,"createdBy":"TAYLORT","dateCreated":"2017-11-27","modifiedBy":"ONEDATA","dateModified":"2017-11-27","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"2008537","version":"1","preferredName":"Diagnosis","preferredDefinition":"the process of identifying a disease by the signs and symptoms (NCI Glossary).","longName":"DX","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B205508C-8324-69B0-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-17","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-17","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"6679216","version":"1","preferredName":"Exocrine Pancreatic Cancer TNM Finding v8 American Joint Committee on Cancer T Category Category","preferredDefinition":"A finding about one or more characteristics of exocrine pancreatic cancer, following the rules of the TNM AJCC v8 classification system. This classification applies to pancreatic ductal adenocarcinoma, acinar cell carcinoma, intraductal papillary mucinous neoplasm with associated invasive carcinoma, intraductal tubulopapillary neoplasm with associated invasive carcinoma, colloid carcinoma, mucinous cystic neoplasm with associated invasive carcinoma, solid pseudopapillary neoplasm, large cell neuroendocrine carcinoma, small cell neuroendocrine carcinoma, and pancreatoblastoma. Well-differentiated neuroendocrine tumors are not staged using this staging system. (from AJCC 8th Ed.):A group formed for the purpose of developing a system of clinical staging for cancer that is acceptable to the American medical profession and is compatible with other accepted classifications.:One criteria of the TNM staging system. T refers to the extent of tumor involvement at the primary site (T, followed by a number indicating size and depth of invasion).:A grouping of items based on some commonality or by user defined characteristics.","longName":"C134877:C39315:C25728:C25372","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Exocrine Pancreatic Cancer TNM Finding v8","conceptCode":"C134877","definition":"A finding about one or more characteristics of exocrine pancreatic cancer, following the rules of the TNM AJCC v8 classification system. This classification applies to pancreatic ductal adenocarcinoma, acinar cell carcinoma, intraductal papillary mucinous neoplasm with associated invasive carcinoma, intraductal tubulopapillary neoplasm with associated invasive carcinoma, colloid carcinoma, mucinous cystic neoplasm with associated invasive carcinoma, solid pseudopapillary neoplasm, large cell neuroendocrine carcinoma, small cell neuroendocrine carcinoma, and pancreatoblastoma. Well-differentiated neuroendocrine tumors are not staged using this staging system. (from AJCC 8th Ed.)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"3"},{"longName":"American Joint Committee on Cancer","conceptCode":"C39315","definition":"A group formed for the purpose of developing a system of clinical staging for cancer that is acceptable to the American medical profession and is compatible with other accepted classifications.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"T Category","conceptCode":"C25728","definition":"One criteria of the TNM staging system. T refers to the extent of tumor involvement at the primary site (T, followed by a number indicating size and depth of invasion).","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Category","conceptCode":"C25372","definition":"A grouping of items based on some commonality or by user defined characteristics.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"848D747E-5094-5CE6-E053-F662850AE994","latestVersionIndicator":"Yes","beginDate":"2019-03-20","endDate":null,"createdBy":"TAYLORT","dateCreated":"2019-03-20","modifiedBy":"ONEDATA","dateModified":"2019-03-20","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"AJCC Based:Staging Criteria Based on American Joint Committee on Cancer System","workflowStatus":"RELEASED","registrationStatus":"Standard","id":"5EFCE404-B4D2-352A-E053-F662850A3F35","latestVersionIndicator":"Yes","beginDate":"2017-11-27","endDate":null,"createdBy":"TAYLORT","dateCreated":"2017-11-27","modifiedBy":"TAYLORT","dateModified":"2019-05-03","changeDescription":"5-3-19 released; tmt. 3/20/19 Edits per AJCC Ed. 8; tmt. 11/27/17 tt created for standardization; supercedes VD 3452421.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[{"publicId":"5506114","version":"1","longName":"Pancreas","context":"MCL","ClassificationSchemeItems":[{"publicId":"5854655","version":"1","longName":"Pancreas Core","context":"MCL"},{"publicId":"7781144","version":"1","longName":"Pancreas PCA Pilot","context":"MCL"}]},{"publicId":"5574838","version":"1","longName":"Staging/Extent of Disease","context":"NCI Standards","ClassificationSchemeItems":[{"publicId":"10000091","version":"1","longName":"Pancreatic","context":"NCI Standards"},{"publicId":"6005920","version":"1","longName":"AJCC Edition 8","context":"NCI Standards"}]},{"publicId":"6437797","version":"1","longName":"Pre-Cancer Atlas Pilot","context":"MCL","ClassificationSchemeItems":[{"publicId":"7001793","version":"1","longName":"Pancreas PCA Pilot","context":"MCL"}]}],"AlternateNames":[{"name":"MCL","type":"USED_BY","context":"MCL"},{"name":"exocrine_clinical_T_AJCC_8","type":"MCL Alt Name","context":"NCI Standards"}],"ReferenceDocuments":[{"name":"Clinical T category","type":"Preferred Question Text","description":"Clinical T category","url":null,"context":"NCI Standards"},{"name":"MCL-PCA-1","type":"Alternate Question Text","description":"Exocrine Clincial T","url":null,"context":"MCL"},{"name":"MCL-Template Name","type":"Data Collection Template","description":"pancreas_v0-1_template-1.xlsx","url":"https://mcl.nci.nih.gov/resources/standards/mcl-cdes","context":"MCL"}],"origin":"AJCC Based:Staging Criteria Based on American Joint Committee on Cancer System","workflowStatus":"RELEASED","registrationStatus":"Standard","id":"5AE5431B-8A39-769F-E053-F662850A928C","latestVersionIndicator":"Yes","beginDate":"2017-10-06","endDate":null,"createdBy":"TAYLORT","dateCreated":"2017-10-06","modifiedBy":"COLBERTM","dateModified":"2021-09-16","changeDescription":"8/17/21 mr Added Alt Name, Ref Doc, to match MCL DD. 5-3-19 released; tmt. 3/20/19 Edits per AJCC Ed. 8; tmt.  11/27/17 tt associated with VD and CS/CSI. 10/6/17 tt Created for standard harmonization. Incomplete pending updates to VD per NCIt Ed 8 caDSR concept loading; supercedes CDE 3452490.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}